{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:43Z","timestamp":1753891963790,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> The impact of non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and tumor necrosis factor inhibitors (TNFi) on the outcomes of mild-moderate COVID-19 in patients with ankylosing spondylitis (AS) remains unclear. This study aimed to evaluate the effects of NSAIDs, csDMARDs, and TNFi on AS patients with mild-moderate COVID-19.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This cohort study utilized patient-reported PCR\/antigen tests to determine the occurrence of COVID-19 and assessed clinical manifestations to determine its severity. The study focused on two primary outcomes: an increased number of COVID-19 symptoms and a prolonged disease course (longer than 10 or 28 days). Modified Poisson regression was performed to analyze the association between exposures and outcomes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 521 patients were included in the analysis. The median age was 34.8 (inter-quartile range: 27.2\u201346.7), with 420 (80.6%) being men. Among the patients, 52 (10.0%) had comorbidities and 443 (85%) had been vaccinated. After adjusting for confounding factors, there was no significant association between csDMARDs or TNFi and the presence of more than 5 symptoms in mild-moderate COVID-19 (adjusted relative risk (RRa) 1.08, 95% CI: 0.84\u20131.40 or 1.09, 0.92\u20131.29 for csDMARDs or TNFi, respectively), whereas the prevalence of experiencing more than 5 symptoms increased in patients with NSAID monotherapy (RRa 1.22, 95% CI: 1.01\u20131.46). Similarly, there was no significant association with having more than 10 symptoms (RRa 0.65, 95% CI: 0.26\u20131.64; 0.95, 0.36\u20132.54; and 1.01, 0.53\u20131.91 for NSAIDs, csDMARDs, and TNFi, respectively). Patients who had pre-existing use of NSAIDs, csDMARDs and TNFi had similar odds of experiencing a disease course longer than 10 days (RRa 1.17, 95% CI: 0.82\u20131.66; 1.18, 0.78\u20131.77; and 1.22, 0.92\u20131.63 for NSAIDs, csDMARDs, and TNFi, respectively) and longer than 28 days (RRa 0.94, 95% CI: 0.31\u20132.81; 0.97, 0.25\u20133.74 and 1.05, 0.44\u20132.49, respectively) compared to those not using medication.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> AS patients treated with csDMARDs or TNFi did not show inferior outcomes in terms of symptom burden or recovery compared to those not using medication in mild-moderate COVID-19. The observed inverse association between pre-existing NSAIDs use and COVID-19 symptom burden in AS deserves further investigation.<\/jats:p>","DOI":"10.3389\/fphar.2023.1266915","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:42:18Z","timestamp":1698640938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","article-title":"Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study","volume":"10","author":"Abu Esba","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/1756-185X.14494","article-title":"How long is long COVID","volume":"26","author":"Baimukhamedov","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"B3","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jama.2012.9282","article-title":"Association of weight status with mortality in adults with incident diabetes","volume":"308","author":"Carnethon","year":"2012","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-cov-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis. Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"m1086","DOI":"10.1136\/bmj.m1086","article-title":"COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists","volume":"17","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40744-022-00462-9","article-title":"COVID-19 outcomes and vaccination in patients with spondyloarthritis","volume":"9","author":"Deodhar","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2665-9913(21)00104-1","article-title":"Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC clinical characterisation protocol UK cohort: a matched, prospective cohort study","volume":"3","author":"Drake","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B10","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"volume-title":"Diagnosis and treatment protocol for COVID-19 in China (trial version 10)","year":"2023","key":"B11"},{"key":"B12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/d41586-023-01577-x","article-title":"Daily briefing: COVID-19 is no longer an international health emergency","volume":"9","author":"Graham","year":"2023","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"833967","DOI":"10.3389\/fpubh.2022.833967","article-title":"Targeting TNF-\u03b1 for COVID-19: recent advanced and controversies","volume":"11","author":"Guo","year":"2022","journal-title":"Front. Public. Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/thoraxjnl-2020-216422","article-title":"Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people","volume":"76","author":"Hopkinson","year":"2021","journal-title":"Thorax"},{"key":"B16","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e15003","DOI":"10.1111\/dth.15003","article-title":"Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis- A population-based cohort study","volume":"34","author":"Kridin","year":"2021","journal-title":"Dermatol. Ther. Dermatol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2021-221575","article-title":"Risk and prognosis of SARS-cov-2 infection and vaccination against SARS-cov-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations","volume":"81","author":"Kroon","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s42977-023-00159-2","article-title":"Do pathogens always evolve to be less virulent? The virulence-transmission trade-off in light of the COVID-19 pandemic","volume":"74","author":"Kun","year":"2023","journal-title":"Biol. Futur."},{"key":"B20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/ard-2022-223499","article-title":"Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries","volume":"82","author":"Machado","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","article-title":"Attributes and predictors of long COVID","volume":"27","author":"Sudre","year":"2021","journal-title":"Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/j.eclinm.2023.101981","article-title":"Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study","volume":"5","author":"Sun","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis. Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcph.1348","article-title":"The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought?","volume":"59","author":"Wro\u0144ski","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am. J. Epidemiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1266915\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:42:24Z","timestamp":1698640944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1266915\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":27,"alternative-id":["10.3389\/fphar.2023.1266915"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1266915","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"article-number":"1266915"}}